322 related articles for article (PubMed ID: 1260780)
1. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
[TBL] [Abstract][Full Text] [Related]
3. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
4. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
5. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
6. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
7. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
8. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.
Pannuti F; Martoni A; Lenaz GR; Piana E; Nanni P
Cancer Treat Rep; 1978 Apr; 62(4):499-504. PubMed ID: 350387
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary results of treatment of hormone-dependent metastatic carcinoma of the breast with the bromocriptin-medroxyprogesterone acetate combination].
Mussa A; Dogliotti L; Di Carlo F
Minerva Med; 1977 Jun; 68(32):2233-44. PubMed ID: 577604
[TBL] [Abstract][Full Text] [Related]
10. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].
Castiglione M; Cavalli F
Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153
[TBL] [Abstract][Full Text] [Related]
11. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
12. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Ansari TN; Mahmood A; Hussain I; Samad A
J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.
Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt JL; Rose C
Cancer Treat Rep; 1979 Feb; 63(2):171-5. PubMed ID: 376131
[TBL] [Abstract][Full Text] [Related]
16. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
[TBL] [Abstract][Full Text] [Related]
17. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
19. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer.
Goss PE; Ashley S; Powles TJ; Coombes RC
Cancer Treat Rep; 1986 Jun; 70(6):777-9. PubMed ID: 2942246
[TBL] [Abstract][Full Text] [Related]
20. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
